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ABSTRACT
When a mammalian cell suffers DNA damage, DNA damage signaling responses
and repair pathways are invoked. The phosphorylation of histone variant H2AX (γH2AX)
and of replication protein A (pRPA) are two well-documented damage signals, marking
double strand breaks and stalled replication forks, respectively. Inhibitors of thymidylate
synthase (TS) and ribonucleotide reductase (RNR) are chemotherapeutics that act by
depriving cells of the deoxynucleotides necessary for DNA synthesis, which causes
damage. The response and repair pathways activated by these chemotherapeutics have
been studied for a number of years but there remain unanswered questions as to how
cancer cells perceive this damage, the kinases active in the response, and the promotion
of damage repair. To investigate the damage response and the necessity of H2AX
phosphorylation during TS inhibition, we utilized cell models in which H2AX has been
knocked out genetically as well as a shRNA H2AX knockdown cell line. Cell survival
assays and immunofluorescence for the homologous recombination (HR) protein RAD51
showed that H2AX mutation or deficiency do not affect cell sensitivity or HR damage
response. However, significant differences in the kinetics of pRPA were noted: pRPA
was seen as early as 4 h post TS inhibition in H2AX deficient cells compared to up to 24
h in H2AX proficient cells. The data suggests that H2AX signaling is not involved in the
response to TS inhibition but may affect the repair pathway selection. A kinase known to
be over-expressed in cancer and act in mitosis, polo-like kinase 1 (PLK1), has recently
gained attention for its reported activity in S-phase stress. Therefore, we examined how
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PLK1 inhibition during deoxynucleotide deprivation affected response and repair of
DNA damage. Our research suggests that inhibition of PLK1 decreases pRPA during
replication stress as well as affects the formation of RAD51 foci in response to damage.
Overall, the data presented here re-enforce the notion that though replication stress
inducers have been researched and used in chemotherapy for decades, aspects of the
damage response are still unknown. As well, our data highlights the potential for new
chemotherapeutic combinations of replication stress inducers with drugs that inhibit
pRPA or PLK1 inhibitors.
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PREFACE
The following pages represent my three years of research in graduate school.
Chapter 1 is an introduction to familiarize the reader with the world of cancer cell
replication, replication stress and how it is induced, and the DNA damage that occurs in
response to replication stress. I’ve chosen to present Chapter 1 as a brief overview of the
molecular events that occur during replication stress and DNA damage response.
Chapters 2 and 3 are meant to be read as individual scientific papers that represent
research on different proteins; however, both chapters focus on one overall hypothesis:
Elevated replication stress in cancer cells is an important weakness of cancer cells that is
therapeutically exploitable.
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CHAPTER 1
INTRODUCTION
1.1 DNA REPLICATION IN CANCER CELLS
During DNA synthesis of both non- and cancerous cells, events are precisely
orchestrated to replicate the DNA without error. A number of start points, termed origins
of replication (OR), exist in the mammalian chromosome which are initiated for DNA
synthesis (Burhans, 1990). As seen in Figure 1.1, replication progresses away from the
OR in a bidirectional fashion, creating a two-forked replication bubble (Burhans, 1990).
At each replication fork, the replication machinery acts to separate the DNA double helix
and to copy both the leading and lagging strands in the 5’ to 3’ direction (Figure 1.2).
Replication protein A (RPA) binds to the single-stranded DNA (ssDNA) to keep the
strands from re-annealing to one another as the topoisomerase-helicase complex and
polymerases act in concert to unwind the parental DNA and replicate both strands,
respectively (Wold, 1997). The DNA polymerases epsilon and delta replicate the leading
and lagging template strands, respectively, by recognizing the template base and pairing
it with the complement nucleotide (Burgers, 1998), extending the newly synthesized
DNA strands. If replication is blocked ahead of the fork or if the replication machinery
becomes inhibited, DNA replication will not be able to continue.
Mammalian cells must accurately replicate DNA during the synthesis phase (Sphase) of the cell cycle to ultimately pass the genetic information from the parent cell to
two identical daughter cells. Cellular proliferation in non-cancerous cells undergo a
1

Figure 1.1. The Replication Bubble. Upon activation of an origin of replication (OR), replication
progresses away from the OR, bidirectionally. Due to the directionality of DNA, each strand must be
synthesized in the 5’ to 3’ direction, creating the necessity for a leading, continuously replicating strand
(red) and a lagging, discontinuously replicating strand (blue). [Image produced by Dr. Aga Gambus,
University of Birmingham, UK: http://www.birmingham.ac.uk/research/activity/mds/domains/Cancer/
cancer-genetics-dna-damage/chromosomal-replication/index.aspx]

Figure 1.2. Machinery at the Replication Fork. The replication fork machinery, also termed the replisome,
ensures the precise replication of both the leading and lagging strand template to duplicate DNA during Sphase. A few key proteins involved in replication are the DNA polymerases (yellow/orange rectangles), the
helicase (blue triangle), the topoisomerase (green circle around DNA helix), and the single strand binding
proteins (RPA; small purple circles). [Rouzer, C. A. (2011) VICB Communications, Vanderbilt Institute of
Chemical Biology: http://www.vanderbilt.edu/vicb/DiscoveriesArchives/dnareplication_ipond.html]

stringent checks-and-balance system to ensure proper, precise replication of DNA and its
segregation into the resultant daughter cells. These checks-and-balances, or cell cycle
checkpoints, have been identified in all phases (Figure 1.3) and are necessary for errorfree, faithful completion of the cell cycle to maintain genetic integrity. However, cancer
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cells often acquire mutations in specific genes that control cell cycle checkpoints that
alter or inhibit their activation and allow for numerous cell divisions, among other
hallmarks of cancer (Hanahan and Weinberg, 2000). During replication of non-cancerous
cells, the intra-S-phase checkpoint is activated when cells encounter DNA damage to
ensure that the DNA is repaired and duplicated in its entirety without error (Willis and
Rhind, 2009; Andrews and Clarke, 2005). The activation of this checkpoint can lead to
the cells arrested in S-phase to allow for the repair of DNA damage (Abraham, 2001; Ye,
2003; Zhang, 2006). Cancer cells often escape the S-phase arrest due to the mutations in
the intra-S-phase checkpoint, allowing for the accumulation of replication errors and
further propagating mutated DNA (Willis and Rhind, 2009). Exploitation of the inherent
mutations in the S-phase checkpoint may produce novel methods and targets to kill
cancer cells.

Figure 1.3. The Stages of the Cell Cycle and Its Checkpoints. The mammalian cell cycle consists of four
stages: Gap1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis (M). The ‘stops’ indicate the checkpoints within
each stage of the cell cycle that regulate the progression of the cell through interphase (G1, S, G2) and into
M, before the final stage of the cycle where the cellular material is divided into two cells, during
cytokinesis. [The Cell, Fourth Edition, Figure 16.8]
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1.2 DNA REPLICATION STRESS
DNA replication stress is defined as inefficient DNA replication that causes DNA
replication forks to progress slowly or stall (Burhans and Weinberger, 2007). Replication
stress is gaining acceptance as a fundamental cause of genome instability that drives
tumorigenesis (Burrell, 2013; Barlow 2013). Replication stress is also a means by which
several classes of anticancer chemotherapeutics act to kill cancer cells. Induction of
replication stress during S-phase activates complex DNA damage response and repair
cascades involving the replication stress sensor Ataxia-telangiectasia and Rad3-related
(ATR) kinase and the phosphorylation of several downstream targets such as checkpoint
kinase 1 (CHK1) (Zhou, 2000; Ward and Chen, 2001), as seen in Figure 1.4. There are
two key signaling events that occur in response to DNA damage in S-phase:
phosphorylation of histone variant H2AX (not shown in Figure 1.4) and phosphorylation
of RPA (shown in Figure 1.4). H2AX phosphorylated at serine-139 (γH2AX) is well
known to be an essential component of DNA double strand break (DSB) repair caused by
ionizing radiation (Celeste, 2002; Xie, 2007). RPA is a heterotrimeric protein, and the
32kDa subunit (RPA2) becomes hyperphosphorylated (pRPA2) on its N-terminus in
response to replication stress (Liu, 2006; Byun, 2005; Binz, 2004). Our lab has also
shown that certain chemotherapeutics induce pRPA2 (Yang, 2008; Yang 2012).
However, there remain important questions regarding exactly how cancer cells respond to
the replication stress induced by a type of stress called deoxynucleotide deprivation.
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Figure 1.4. Replication Stress Response at the Replication Fork. When cells are stressed with
chemotherapeutics that induce replication stress, several DNA damage response proteins are recruited to
the replication fork to stabilize the fork and to activate repair of the damage. If the replication stress cannot
be overcome, evidence suggests that stalled forks are collapsed and processed into DSBs. [Nature Reviews
Molecular Cell Biology (2008) 9: 616-627.]

Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase (shown in Figure
1.4), canonically a mitotic regulation protein, that is over-expressed in many cancers
including breast, ovarian, pancreatic, prostate, and colorectal cancer (Takahashi, 2003;
Weichert, 2004; Gray, 2004). Like the over-expression of the proto-oncogene HER2
(Ménard, 2000), the over expression of PLK1 qualifies it as oncogenic (Jang, 2006;
Pellegrino, 2010). Inhibition of PLK1 by ATP-based inhibitor BI-2536 results in cell
cycle arrest at pro-metaphase (Steegmaier, 2007). Several more recent studies have
implicated oncogenic PLK1 as actively participating in overcoming replication stress
(Trenz, 2008; Song, 2011; Song 2013; Yata, 2012). Also, it has been shown that PLK1
activity is suppressed in Ataxia-telangiectasia mutated (ATM) and ATR-activated cells
(van Vugt, 2001) through the binding of the tumor suppressor BRCA1 to PLK1 (Zou,
2013). Conversely, in cells depleted of ATR and treated with replication stress inducers,
PLK1 activity has been shown to suppress replication restart; inhibition of PLK1 in
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combination with RNF4 inhibition allowed for limited replication and decreased DSB
formation (Ragland, 2013). The current literature suggests an active role for oncogenic
PLK1 in regulating replication progression during replication stress, involvement in
replication fork collapse, and the activation of DSB repair mechanisms to promote
resistance to replication stress, little of which is fully understood. Therefore, the role of
PLK1 in response to replication stress caused by chemotherapeutic agents needs further
investigation.

1.3 DEOXYNUCLEOTIDE DEPRIVATION
Deoxynucleotides

such

as

thymidylate

monophosphate

and

cytidine

monophosphate are the building blocks of DNA replication. When deoxynucleotide pools
are imbalanced or decreased overall, replication forks cannot progress forward, among
other

serious

consequences

(James,

1997;

Song,

2003;

Chabosseau;

2011).

Chemotherapeutics that induce replication stress by deoxynucleotide deprivation such as
Hydroxyurea (HU) and fluoropyrimidines have been studied for fifty years or greater.
HU inhibits the formation of deoxynucleotides cytidine, adenosine, and guanosine by
binding to the enzyme ribonucleotide reductase (RNR) which quenches the free tyrosyl
radical at the active site, inactivating RNR (Yarbro, 1992). The fluoropyrimidine 5fluoro-2’-deoxyuridine (FdUrd) and some folate antimetabolites (or antifolates) inhibit
the de novo synthesis of thymidylate (dTMP) by inhibiting the enzyme thymidylate
synthase (TS). Specifically, FdUrd is phosphorylated to form FdUMP which binds to the
deoxyuridine monophosphate (dUMP) site on TS, forming an irreversible covalent
tertiary complex with methyl-tetrahydrofolate (MTHF) (Figure 1.5; Vazquez-Padua,
1989). Ultimately the de novo synthesis of dTTP decreases. Two antifolate-based
6

inhibitors, Pemetrexed (PMX) and Raltitrexed (RTX), inhibit TS as well as other
enzymes involved in folate metabolism and the synthesis of deoxynucleotides (Adjei,
2004; Van Cutsem, 2002). Inhibition of RNR or TS causes depletion of the
deoxynucleotide pools necessary for DNA synthesis. However, the precise mechanisms
by which cancer cells respond to replication stress caused by deoxynucleotide deprivation
are unclear.

Figure 1.5. The Inhibition of Thymidylate Synthase by FdUrd. Once inside the cell, FdUrd is
phosphorylated to the monophosphate FdUMP which then binds to TS, forming an irreversible covalent
tertiary bond with methyl-tetrahydrofolate (CH2THF), inhibiting the de novo synthesis of thymidylate.
[Longley et al. (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer
(3): 330-338.]

1.4 DAMAGE RESPONSE
Both HU and TS inhibitors are known to induce γH2AX (Ward and Chen, 2001;
Yang, 2008; Luo, 2008). However, recent observations have questioned the necessity of
H2AX in the actual repair of some damage induced by chemotherapeutics, despite the
robust induction of γH2AX by these agents (Revet, 2011; Cleaver, 2011). In other words,
although some DNA damaging agents such as cisplatin induced γH2AX, H2AX deficient
cells were not sensitized to cisplatin compared to cells expressing wild-type H2AX
(Revet, 2011). Our lab and others have shown that RPA2 is hyperphosphorylated when
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cells are treated with these drugs (Yang, 2008; Yang 2012). Though TS inhibitors have
been studied, it remains unclear whether the stress caused by TS inhibitors is perceived
by the cell to predominantly be a ‘stalled replication fork (pRPA2)’ or a ‘DNA double
strand break (γH2AX).’
Another important question is how the DNA repair machinery is engaged to repair
the damage. The collapse of the stalled replication fork is becoming more widely
recognized as an active event (Sirbu, 2011; Forment, 2011); the collapsed fork is then
processed to form a DSB which can then be repaired by two pathways: homologous
recombination (HR) and non-homologous end joining (NHEJ). The selection and
activation of the DSB repair pathway is largely variable with many proteins driving both
pathways

(Shrivastav,

2008);

DSB

repair

pathway selection resulting

from

deoxynucleotide deprivation is unclear as well.
Lastly, what signaling kinases are involved in driving resolution of the damage?
Well-known are the damage response kinases ATM and ATR which initiate the DNA
damage response and repair cascades. Still, the current literature suggests an active role
for the oncogenic PLK1 kinase in replication fork progression, fork collapse, and the
activation of DSB repair mechanisms (Trenz, 2008; Song, 2011; Yata, 2012; Ragland
2013). Specifically, PLK1 binds to phospho-Mcm2 when ATR and CHK1 are activated
by replication stress (reviewed in Song, 2012). PLK1 then phosphorylates Claspin, a
necessary interacting protein for CHK1 and ATR, promoting Claspin degradation and
downstream HR events (Trenz, 2008; Yata, 2012). Though data is compiling that PLK1
is necessary for replication progression during replication stress (Ragland, 2013), the
phospho-substrates of the PLK1 kinase during replication stress are still poorly defined.
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Chemotherapy-induced replication stress and the subsequent DNA damage
response is enigmatic in nature. Better understanding how cells respond to this damage
and the exploitation of the genomic instability inherent in all cancer cells will lead to
more efficient chemotherapies. It was therefore decided to exploit cell culture models in
which H2AX was mutated, disrupted, or deleted to test the importance of H2AX
signaling in response to TS inhibition. As well, we investigated the role of oncogenic
PLK1 activity in replication stress induced by deoxynucleotide deprivation using wellcharacterized human colorectal cancer cell lines.
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CHAPTER 2
H2AX AND ITS PHOSPHORYLATION ARE DISPENSABLE IN THE CELLULAR
RESPONSE TO REPLICATION STRESS
2.1 INTRODUCTION
DNA replication is a precisely timed and executed event that occurs once in every
S-phase of the cell cycle to duplicate the genetic material, which is eventually separated
into two daughter cells during mitosis (Figure 1.3). Disruption of the S-phase to activate
the intra-S-phase checkpoint has been the objective of several classes of anticancer
chemotherapeutics to kill cancer cells (Karnani and Dutta, 2011). Specific inhibition of
enzymes such as ribonucleotide reductase (RNR) or thymidylate synthase (TS) by
chemotherapeutics causes deoxynucleotide deprivation, which induces replication stress.
The cellular response to replication stress involves a cascade of DNA damage response
and repair proteins acting in concert to detect and attempt repair of the damage.
S-phase DNA damage activates the replication stress sensor Ataxia-telangiectasia
and Rad3-related (ATR) kinase which phosphorylates several downstream targets (Flynn
and Zou, 2011). Two of these downstream targets are well-documented signals of DNA
damage in S-phase: the hyperphosphorylation of the single-stranded binding protein,
replication protein A on the 32 kDA subunit (pRPA2) and the phosphorylation of histone
variant H2AX (γH2AX) (Ward and Chen, 2001; Binz, 2004; Liu, 2006; Yang, 2008).
RPA2 hyperphosphorylation is recognized as the marker for stalled replication forks (Liu,
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2006; Binz, 2004). γH2AX is traditionally recognized as a biomarker for DNA DSB
repair induced by ionizing radiation (Celeste, 2002; Xie, 2007). Inductions of both
pRPA2 and γH2AX in response to TS inhibitors have been reported in the literature
(Ward and Chen, 2001; Yang, 2008; Luo, 2008; Yang 2012). This induction of γH2AX
by TS inhibition suggests that deoxynucleotide deprivation causes DSBs. However, the
necessity of H2AX phosphorylation in signaling and repair of some DNA damage has
been questioned, despite the robust induction of γH2AX by certain chemotherapeutics
(Cleaver, 2011; Revet, 2011). For instance, Revet et al. 2011 reported that though the
DNA damaging agent cisplatin induced γH2AX, H2AX deficient cells were not
sensitized to the drug compared to cells expressing wild-type H2AX. We then questioned
the importance of H2AX signaling in response to TS inhibition.
How cancer cells perceive damage signals from replication stress induced
deoxynucleotide deprivation is largely unknown. Our lab has endeavored to resolve
whether this damage is perceived as a ‘stalled replication fork’ (pRPA2) or a ‘DNA DSB’
(γH2AX) as well as the necessity of H2AX signaling in response to TS inhibitors. Here
we have utilized the TS inhibitor 5-fluoro-2’-deoxyuridine (FdUrd) to induce replication
stress to study the early cellular responses and the necessity of H2AX phosphorylation in
responding to replication stress in cell models with wild-type or altered H2AX status. Our
data suggests that H2AX and its phosphorylation are not involved in the repair response
to TS inhibition.
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2.2 MATERIALS AND METHODS
To examine the effect of H2AX signaling in response to TS inhibition, we utilized
three models that have reduced or eliminated H2AX expression. First, murine embryonic
fibroblasts (MEFs) were generated by others, in which the H2AX gene was disrupted to
generate H2AX-/- cells (Celeste, 2002). From these H2A

-/-

MEFs, stable sublines were

generated which contain an empty vector (EV, H2AX null), or add-back sublines
containing a vector expressing full-length, wild-type H2AX (WT), or a serine to alanine
(S139A) H2AX mutant (Mut) incapable of phosphorylation, which were obtained from
Dr. James Cleaver at UCSF (Revet, 2011). It is important to note that cells containing
WT or Mut H2AX were tagged by the FLAG protein, which increases the total kiloDalton weight of the protein. The next model was the human breast epithelial cell line
MCF10A and a subline in which H2AX was eliminated by gene targeting (H2AX-/-). In
addition, we used the colorectal carcinoma cell line HCT116 in which H2AX was
silenced by shRNA, reducing expression of H2AX by 70-80% as measured by Western
blotting (Figure A.1). This cell line was developed by the Shtutman Lab.
All cell lines were grown in a 37°C incubator at 5% CO2 and maintained in media
specific to each cell line. The MCF10A cells were grown in DMEM-HAM’s medium
with 5% horse serum, 10 μg/mL human insulin, 0.5 μg/mL hydrocortisone, 10 ng/mL
epidermal growth factor (EGF), and 100 ng/mL cholera toxin. Freeze-thaw cycles were
carefully noted for the EGF due to the sensitivity of the MCF10A cells to changes in the
EGF. MEF cells were maintained in MEM/EBSS medium with 10% Fetal Bovine Serum
(FBS), 25 μg/mL Blasticidin, 10 units/mL Pen/Strep, and supplemented with 100 nM
Folinic Acid. HCT116 cells were maintained in RPMI 1640 medium with 10% heat-
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inactivated FBS, 1% Pen/Strep, 2 μg/mL Puromycin and supplemented with 100 nM
Folinic Acid.
To induce replication stress via deoxynucleotide deprivation, we utilized known
TS and RNR inhibitors such as 5-fluoro-2’-deoxyuridine, hydroxyurea (HU), pemetrexed
(PMX), and raltitrexed (RTX). Specifically the antimetabolite 5-fluoro-2’-deoxyuridine
(FdUrd) was utilized. Briefly, FdUrd is converted in the cell to 5-fluoro-2’-deoxyuridine
monophosphate (FdUMP), which then covalently binds to and inhibits TS [reviewed in
Touroutoglou and Pazdur, 1996].
To measure the toxicity of the TS inhibition, the MTT (3-[4, 5-dimethylthiazol-2yl] 2, 5-diphenyltetrazolium bromide) assay was utilized. Specifically, 2000 cells each
were plated into the wells of a 96-well plate and allowed to attach overnight in a 37°C
incubator at 5% CO2. Cells were then treated for 24 h with drug-containing medium
which was then removed and replaced with drug-free media and replaced in the incubator
for at least 3 days or until the control wells were confluent. Each plate was then
processed as follows: MTT was added to each cell-containing well and incubated for 5 h,
plates were spun down for 5 min at 1100 rpm, media was aspirated and dissolved in 200
μL of dimethyl sulfoxide (DMSO), and the absorbance of each well was measured at 595
nm. Data replicates were averaged and plotted as the cell survival versus drug
concentration using Excel. Each data point is representative of 2 or 3 independent
experiments, as noted in the figure legend.
To measure the kinetics of H2AX and RPA phosphorylation in cells that are
deficient in H2AX, MCF10A and MEF cells were plated into 100 mm dishes, grown to
~60-70% confluence, and then treated at specific time-points (0, 4, 6, 8, 12, and 24 h)
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with FdUrd. Cell extracts were then collected using two cell fraction kits: NE-PER®
Nuclear and Cytoplasmic Extraction Reagents and Subcellular Protein Fractionation Kit
for Cultured Cells (Thermo Scientific). Protein extracts were then separated on 12%
acrylamide denaturing gels, transferred to PVDF membranes, and probed with specific
antibodies: H2AX (Cell Signaling), γH2AX (Trevigen), RPA2 (Abcam), pRPA2 (Bethyl
Laboratories), and β-actin (Abcam). Western blots shown are representative results of 2
independent experiments.
To examine the formation of RAD51 foci, MEF cells were plated at 50,000
cells/well onto coverslips in a 6-well plate and treated for 24 h with 10 μM FdUrd. Cells
were then proceeded as follows: fixed with 4% formaldehyde in PBS, permeabilized with
0.3% Triton x-100/0.01 M Glycine in PBS, blocked for 1 h with 1% bovine serum
albumin (BSA) in PBS, probed overnight at 4°C with anti-RAD51 antibody (Santa Cruz),
and probed with secondary Texas Red antibody (Invitrogen) for 1 hour at room
temperature. Coverslips were then removed and mounted using Prolong Gold Anti-fade
with DAPI and sealed with Permount. Cells were imaged using an Olympus LX81 at
100x and images processed using MetaMorph software.

2.3 RESULTS AND DISCUSSION
Using the three cell lines described, we endeavored to examine whether cells that
have reduced or eliminated H2AX expression were more sensitive to TS inhibition
compared to the wild-type (WT) expressing cells. All cell lines were treated for 24 h with
FdUrd, followed by three days of recovery in drug-free media. As evident by Figure 2.1
A, H2AX deficiency in non-tumorigenic breast epithelial cells (MCF10A) does not
increase sensitivity to treatment with FdUrd. Similarly, Figure 2.1 B shows that H2AX
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mutation of serine-139 to a non-phosphorylatable alanine (S139A) mutant or deficiency
in the gene does not impart sensitivity in mouse embryonic fibroblasts (MEFs). At
concentrations greater than 1 μM of FdUrd, the H2AX-null (EV) and H2AX S139A
mutant (Mut) cells may be slightly more resistant than the WT expressing cells. This
resistance may be attributed to the lack of S139 phosphorylation which acts as a binding
site for DNA damage sensing proteins (Singh, 2012). Finally, reduced expression of
H2AX by shRNA in colorectal carcinoma HCT116 cells (Figure 2.1 C) did not increase
sensitivity to TS inhibition. Similar toxicity profiles were obtained when the cells were
treated with the alternative chemotherapeutics Pemetrexed (PMX) and Raltitrexed (RTX)
that induce deoxynucleotide deprivation (Figure A.2 and A.3).
We then examined the ability of MEF H2AX S139A mutant or deficient cells to
form RAD51 foci, indicative of homologous recombination (HR). Figure 2.2 shows
representative images of MEF sub-lines WT, EV, and Mut exposed to 10 μM FdUrd for
24 h and probed for the HR protein RAD51. The yellow arrows point to RAD51 foci that
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Figure 2.1. FdUrd-Treated Cell Survival Curves. A) Non-tumorigenic breast epithelial MCF10A that are
H2AX proficient (+/+) or deficient (-/-). B) Murine embryonic fibroblasts with wild-type (WT), S139A
mutant (Mut), or H2AX null (EV). C) Colorectal carcinoma HCT116 cells with WT or reduced (KD)
H2AX expression. Cells were treated for 24 h with FdUrd concentrations in Folinic Acid-containing media.
Blue lines with diamond data points represent cells with wild-type H2AX, red lines with square data points
represents cells with decreased expression of H2AX or are H2AX-/-, and green lines with triangle data
points are cells expressing the S139A H2AX mutant. Each data point represents n=2 in MEFs and HCT116
or n=3 in MCF10A.

have formed in the MEF sub-lines, indicating that S139A mutation or deficiency in
H2AX do not impair foci formation (overlay images, Figure A.4). Results from the cell
survival assays and immunofluorescence images suggest that H2AX signaling is not
involved in the repair responses to deoxynucleotide deprivation caused by TS inhibition
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that promote repair and survival. This data is consistent with other published data
(Celeste, 2002; Revet, 2012).
In our investigation of H2AX and its role in replication stress induced by
deoxynucleotide depriviation, we initially focused on longer time-points (24 h) of drug
treatment. Singh et al. 2012 showed that as early as 15 minutes of ionizing radiation (IR),
there is a strong induction of γH2AX in their cell model; however, little is known about
the early S-phase DNA damage signaling events that occur as a result of TS inhibition.
WT

-

+

Mut

+

-

-

+

RAD51

DAPI

FdUrd:

EV

Figure 2.2. RAD51 Foci Form in H2AX mutant and null MEFs. Wild-type H2AX (WT), H2AX-null (EV),
and H2AX S139A mutant (Mut) MEF sub-lines were treated for 24 h with 10 μM FdUrd and then probed
for the HR protein RAD51. Yellow arrows point to RAD51 foci in the enlarged images of the treated cells.
Blue: DAPI stained DNA; Red: RAD51. All images taken at 100x on the Olympus LX81 microscope and
processed using the MetaMorph software.

Using the H2AX wild-type and deficient MCF10A and MEF cells, we endeavored to
examine the early DNA damage response to TS inhibition using the replication stress
marker pRPA. Specifically, cells were treated for 4, 6, 8, 12, or 24 h with FdUrd,
collected, and processed using protein extraction kits. Figure 2.3 A and B shows the
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MCF10A and MEF H2AX proficient cells, respectively, that have been probed for total
RPA, γH2AX, and pRPA. Induction of γH2AX occurs at different time-points: early, at 4
h, in MCF10A and late, at 24 h, in the MEFs. Phosphorylation of RPA, however, occurs
at 24 h of FdUrd treatment in both H2AX proficient lines. In Figure 2.3 C and D, H2AX
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Figure 2.3. MCF10A and MEFs Respond to Replication Stress. H2AX deficient cells exhibit faster RPA
phosphorylation kinetics than H2AX proficient cells. A) and C) MCF10A H2AX proficient (+/+) and
deficient (-/-) cells, respectively, were treated with 10 μM FdUrd and the cytoplasmic (Cyto) and nuclear
(Nuc) protein extracts were collected. B) and D) MEF H2AX WT and EV cells, respectively, were treated
with 1 μM FdUrd and a subcellular fractionation kit was used to collect the soluble nuclear (Sol. Nuc) and
the chromatin bound (Chr. Bound) extracts. Proteins probed: replication protein A (RPA), phosphorylated
RPA (pRPA), γH2AX, and β-actin for the loading control.

deficient MCF10A and MEF cells do not have γH2AX bands, as H2AX is not expressed
in these lines. But, in both H2AX deficient cell lines, the phosphorylation of RPA occurs
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at time-points as early as 4 h. This data indicates that significant differences in the
kinetics of RPA phosphorylation occur based on H2AX status: H2AX proficient cells
undergo a H2AX dependent signaling pathway which leads to a delayed RPA
phosphorylation and H2AX deficient cells undergo a H2AX independent signaling
pathway, causing an early phosphorylation of RPA. Although the survival data suggest
that H2AX deficiency does not sensitize cells to FdUrd or inhibit the formation of
RAD51 foci, the alteration in pRPA suggestion signaling pathway choice is affected.
Overall, our data indicates that H2AX is not involved in the DNA damage
response initiated by deoxynucleotide deprivation that promotes repair and survival. In
three separate cell lines, we have shown that sensitivity to FdUrd is not altered in H2AX
reduced, mutated, or deficient lines when compared to the wild-type H2AX expressing
cells. Similarly, RAD51 foci formation was unaffected by altered H2AX status. This
suggests that the damage response to deoxynucleotide deprivation from TS inhibition is
more ‘stalled replication fork’ like as opposed to a “DSB”. The finding that the RPA
phosphorylation kinetics change based on H2AX status is a potential point of therapeutic
exploitation. Combination treatments with TS inhibitors and drugs that disrupt pRPA
kinetics of cancer cells may have therapeutic value.
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CHAPTER 3
ONCOGENIC PLK1 ACTIVITY DURING REPLICATION STRESS PROMOTES THE
SIGNALING AND REPAIR OF DNA DAMAGE
3.1 INTRODUCTION
The search for druggable targets that are over-expressed in cancer cells but not in
normal tissue is one of the many goals of cancer research. One such target, polo-like
kinase 1 (PLK1), has been researched for a number of years, and inhibitors of this protein
are currently in clinical trials (Yim, 2013). PLK1 is a serine/threonine protein kinase that
preferentially phosphorylates phospho-proteins, regulates mitotic progression, and is
over-expressed in many cancers including breast, ovarian, pancreatic, prostate, and
colorectal cancer (Takahashi, 2003; Weichert, 2004; Gray, Jr, 2004). Over-expression
qualifies PLK1 as an oncogene and a potential chemotherapy target. One of the PLK1
inhibitors currently in clinical trials is the ATP-based inhibitor BI-2536, which results
cellular arrest early in mitosis, specifically in pro-metaphase (Steegmaier, 2007). Though
PLK1 expression is at its highest in mitosis (Golsteyn, 1994), several recent studies have
shown that oncogenic PLK1 is an active participant in S-phase when replication is
stressed (Trenz, 2008; Song, 2011; Yata, 2012; Song, 2013, Ragland, 2013).
Replication stress is a means by which several classes of anticancer
chemotherapeutics act to kill cancer cells, such as the ribonucleotide reductase (RNR)
inhibitor Hydroxyurea (HU). Inhibition of RNR by HU treatment decreases the
production of deoxynucleotides necessary for DNA synthesis (Yarbro, 1992), thus
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causing an S-phase arrest. Induction of replication stress begins with the increase of
single-stranded DNA (ssDNA) which is then bound by replication protein A (RPA). RPA
is then phosphorylated (pRPA) by the replication stress sensor Ataxia-telangiectasia and
Rad3-related (ATR) kinase, in turn activating complex DNA damage response and repair
cascades (Zhou, 2000), which includes the phosphorylation of CHK1 (Ward and Chen,
2001). Evidence is gathering that suggests that oncogenic PLK1 plays a dynamic role in
how cancer cells respond to damage and overcome replication stress. Oncogenic PLK1 is
suppressed by the activation Ataxia-telangiectasia mutated (ATM) kinase and ATR
during replication stress (van Vugt, 2001; Zou, 2013). However, oncogenic PLK1
inhibits ATR signaling by the phosphorylation of Claspin, a necessary interacting protein
for ATR and CHK1, promoting Claspin degradation and downstream homologous
recombination (HR) events (Trenz, 2008; Yata, 2012).
Questions still remain of how oncogenic PLK1 activity in replication stress
induced by deoxynucleotide deprivation promotes cell survival and whether other
phospho-substrates exist for the kinase. We utilized the colorectal carcinoma cell lines
HT29 and HCT116, replication stress inducer HU, and PLK1 inhibitor BI-2536 to further
explore these questions. Our data shows that PLK1 inhibition during replication stress
decreases RPA phosphorylation, suggesting that phosphorylated RPA may be a substrate
of PLK1. We also provide evidence that the HR protein RAD51 and its foci formation are
affected when PLK1 is inhibited during replication stress, in agreement with other
published data (Yata, 2012).
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3.2 MATERIALS AND METHODS
To study the importance of oncogenic PLK1 activity during replication stress
induced by deoxynucleotide deprivation, we utilized two well-characterized cell lines:
colorectal carcinoma HCT116 and colorectal adenocarcinoma HT29. HCT116 cells were
grown in McCoy’s 5A media, 10% FBS, and 1% Pen/Strep; HT29 cells were grown in
Low Glucose DMEM, 10% FBS, and 1% Pen/Strep. Both cell lines were incubated in a
37°C incubator at 5% CO2. Hydroxyurea (HU) was used to inhibit RNR, resulting in
replication stress. HU prevents the formation of deoxynucleotides by binding to the
enzyme RNR, quenching the free tyrosyl radical at the active site, therefore inactivating
RNR (Yarbro, 1992).
To examine how oncogenic PLK1 and pRPA induction change during replication
stress, HT29 and HCT116 were plated in 60 mm dishes and treated with HU for a total of
18 h. ATP-based inhibitor BI-2536 was then used to inhibit PLK1 activity (Steegmaier,
2007) at specific time-points during replication stress. More precisely, cells were treated
with 5 mM HU to induce replication stress and during the HU treatment, BI-2536 was
added to the media at a final concentration of 30 nM for 6 or 10 h of HU and BI-2536 cotreatment. It is important to note that HU was delivered first to ensure that the cells were
arrested in S-phase before BI-2536 treatment allowing for the study of PLK1 inhibition
specifically during replication stress. At the end of the drug treatment (18 h total HU with
6 or 10 h of BI-2536 co-treatment), cells were trypsinized and lysed using a whole cell
lysis buffer that contained both protease and phosphatase inhibitors to maintain the
protein integrity and phosphorylation, respectively. Extracts were then run on 12% nondenaturing acrylamide gels, transferred to PVDF membranes, and probed with specific
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antibodies: PLK1 (Milllipore), pRPA2 (Bethyl Laboratories), and β-actin (Abcam).
Western blots shown are representative images of 2 independent experiments. Band
intensity measurements were then taken using ImageQuant software.
For immunofluorescence experiments, HT29 and HCT116 were plated at 50,000
cells/well onto coverslips in a 6-well plate and treated with HU and BI-2536 using the
same co-treatment process that was used for Western blotting. At the end of the cotreatments, cells were then processed as follows: fixation with 4% formaldehyde in PBS,
permeabilized with 0.3% Triton x-100/0.01 M Glycine in PBS, blocked for 1 h with 1%
BSA in PBS, probed overnight at 4°C with anti-PLK1 and anti-pRPA2 or RAD51 (Santa
Cruz) alone. After multiple wash steps with 1% BSA-PBS, the cells were probed for 1
hour at room temperature with secondary antibodies Texas Red goat anti-rabbit
(Invitrogen) for pRPA2 or RAD51 and Fluorescin goat anti-mouse (Invitrogen) for
PLK1. The coverslips were then stained with DAPI for 10 minutes and rinsed with PBS.
Finally, the coverslips mounted using DABCO and sealed using clear nail polish. Cells
were imaged using an Olympus LX81 at 100x and images processed using MetaMorph
software. Slides were also viewed on a Nikon Eclipse E600 to quantitate the number of
pRPA2 positive cells. For each treatment, 140-170 cells were scored, the percentage
calculated, and plotted using Excel.

3.3 RESULTS AND DISCUSSION
Oncogenic PLK1 is gaining recognition as an important kinase in the response to
DNA damage. Here we have examined how this canonical mitotic regulation kinase
behaves during deoxynucleotide deprivation and the consequences of inhibiting PLK1
during this type of replication stress. Figure 3.1 shows how PLK1 and pRPA in both
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HT29 and HCT116 responds to HU or BI-2536 treatment alone and in combination. In
the left panel, the PLK1 band in HT29 cells treated with 18 h HU only appears to
decrease in comparison to the untreated cells. This finding is in agreement with the data
published by Zou et al. (2013) who showed that in replication stress induced by HU
treatment, BRCA1 is activated and binds to oncogenic PLK1, down-regulating its kinase
activity, and decreasing the amount of unbound PLK1. It is important to note that in all
HU and BI-2536 co-treatments, HU was delivered first to ensure that the cells were
arrested in S-phase to allow study of the cellular response of PLK1 inhibition during
replication stress. When both cell lines were co-treated with HU and BI-2536, PLK1
decreases relative to the untreated cells. We hypothesize that this band reduction in the

Figure 3.1. Colorectal Carcinoma Cell Lines Co-treated with HU and BI-2536. HT29 and HCT116 show
reduced PLK1 expression in cells co-treated with HU and BI-2536. Both cell lines were treated with 5 mM
HU or 30 nM BI-2536 alone or in combination. At the end of the treatment, whole cell extracts were
collected for Western blotting. Proteins probed: PLK1, phosphorylated RPA (pRPA), and β-actin, used as a
loading control. Images are representative of 2 independent experiments.

co-treated cells could result from the combination of BRCA1 and BI-2536 inhibition
decreasing the amount of unbound PLK1. Cells that were treated with BI-2536 alone
have stronger PLK1 banding than the untreated cells. We believe this is due to the cells
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being arrested in mitosis—the consequence of BI-2536 treatment—where PLK1 levels
are at their highest during the cell cycle (Steegmaier, 2007); similarly, there is a lack of
pRPA in the BI-2536 only treated cells because RPA phosphorylation primarily takes
place in S-phase, not mitosis.
RPA phosphorylation as a result of replication stress was also examined in the
whole cell lysates from the HT29 and HCT116 cells. As expected, there is a strong
induction of pRPA when cells are treated with HU alone. Upon examination of the band
intensity (Figure 3.2), we found that in co-treated cells, the amount of RPA
phosphorylation changes. Specifically, in HT29 extracts (Blue) treated with HU and BI2536, pRPA band intensity decreases to roughly 40 fold change from 50 fold change in
HU only treated extracts. Due to the decrease in phosphorylation that is seen in the co-
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Figure 3.2. pRPA Band Intensity. pRPA band intensity of HT29 cells decreases in HU and BI-2536 cotreatments. RPA phosphorylation in HT29 (Blue) appears to decrease in HU and BI-2536 treated cells
compared to HU alone. HCT116 (red) cell extracts do not behave similarly. Band intensity was first
normalized to β-actin and then the fold change was taken in respect to the untreated control. Intensity
measured using ImageQuant software.

treated extracts, we hypothesize that pRPA may be a target substrate for PLK1
phosphorylation and when oncogenic PLK1 is inhibited by BI-2536 during replication
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stress, the amount of phosphorylated RPA decreases due to this inhibition. HCT116
extracts (Red) do not behave similarly to the HT29 in respect to the pRPA decrease in the
co-treated extracts (Figure 3.2). It is well-documented that there are differences in the
intra-S-phase checkpoint activation of the HT29 cells compared to HCT116 (Parsels,
2004), and that HCT116 cells are defective in a complex that detects and signals DNA
damage (Takemura, 2006).
18 h HU

18 h HU + 6 h BI 18 h HU + 10 h BI

PLK1

pRPA

DAPI

Untreated

Figure 3.3. Immunofluorescence for pRPA and PLK1 in HT29. Oncogenic PLK1 does not form foci or
localize in the nucleus in response to replication stress. pRPA foci size and number appear to decrease in
co-treated cells. HT29 cells were treated with 5 mM HU alone or with 30 nM BI-2536 and probed for
pRPA (Red) and PLK1 (Green) and the DNA stained with DAPI (Blue). All images taken at 100x on the
Olympus LX81 microscope and processed using the MetaMorph software.

We then examined whether oncogenic PLK1 forms foci in response to
deoxynucleotide deprivation and, if foci were present, if they co-localized with pRPA
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foci. PLK1 (green) in HT29 (Figure 3.3) did not form foci when treated with HU and BI2536 co-treatment or HU alone. When cells were treated with BI-2536 only, those cells
arrested in mitosis had pan-nuclear PLK1 staining with localized intense staining at the
ends of the condensed chromosomes (Figure A.5). We also have made the preliminary
observation that cells co-treated with HU and BI-2536 have pRPA foci that appear both
18 h HU

18 h HU + 10 h BI

RAD51

DAPI

Untreated

Figure 3.4. Immunofluorescence for RAD51 in HT29. RAD51 foci in HT29 decrease in size and number
in HU and BI-2536 co-treatments. HT29 cells were treated with 5 mM HU and 30 nM BI-2536 and probed
for RAD51. In the HU and 10 h BI-2536, RAD51 foci appear to be smaller than in the HU only treated
cells. RAD51: Red, and DAPI-stained DNA: Blue. Images were taken on the Olympus LX81 microscope
and processed with the MetaMorph software.

smaller and less numerous than cells treated with HU alone (Figure 3.3). The most
noticeable difference in pRPA foci size and foci is between the HU alone and the Hu +
10 h BI-2536 (enlarged images, Figure 3.3). This observation strengthens our previous
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hypothesis that oncogenic PLK1 further phosphorylates pRPA in response to replication
stress and that the inhibition of PLK1 decreases RPA phosphorylation.
Recently, Yata et al. (2012) reported that RAD51 is phosphorylated in vivo by
PLK1 in response to ionizing radiation and that this phosphorylation is necessary for
DNA damage recognition and recruitment of RAD51 to the damage site. Therefore, we
probed HT29 cells treated with HU alone and in combination with BI-2536 with RAD51
and studied the formation of RAD51 foci in response to our treatment scheme. Figure 3.4
shows RAD51 foci formation as a result of HU treatment as well as the BI-2536 cotreatments. The enlarged immunofluorescent images better show the foci in HU alone
and HU in combination with 10 h of BI-2536. We noted that RAD51 foci appeared
smaller and less numerous in the combination treated HT29 cells. This observation most
likely results from the inhibition of PLK1 by BI-2536, which inhibits the phosphorylation
of RAD51 and subsequent recruitment of RAD51 to the damage site caused by
replication stress.
Our data strengthens the argument that oncogenic PLK1 is essential in the
response of cancer cells to DNA damage (Trenz, 2008; Song, 2011; Yata, 2012; Ragland,
2013). More precisely, we have shown that PLK1 inhibition during replication stress
induced by deoxynucleotide deprivation alters phosphorylation of RPA and potentially
foci size and formation of both pRPA and RAD51. RPA phosphorylation is indicative of
cellular replication stress and acts as a signal to arrest replication and repair damage.
RAD51 foci formation indicates that DNA damage resulting in a DSB has occurred and
the cell is attempting to repair the break by HR. Therefore, oncogenic PLK1 activity
during replication stress promotes cell survival by maintaining the pRPA stress signal and
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phosphorylating RAD51 to promote foci formation and DSB repair. These findings
highlight the potential of replication stress inducers and PLK1 inhibitors as a combination
treatment in cancer chemotherapy.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS
4.1 CONCLUSIONS
Data presented here provides evidence that even though DNA replication and the
response to DNA damage in cancer cells has been studied and exploited for
chemotherapeutic treatment, there are still elements of the replication and damage
response processes that are poorly understood. We have endeavored to specifically
explore the DNA damage response that is activated in cancer cells treated with
chemotherapeutics that induce replication stress as a result of deoxynucleotide
deprivation. By depriving cancer cells of deoxynucleotides necessary for DNA synthesis,
the cells can no longer complete replication, causing the cells to arrest and to initiate
response and repair cascades to attempt repair of the damage. It is the response to the
damage and repair pathway selection that can be targeted for disruption to promote
cancer cell death.
Certain cellular responses such as the phosphorylation of histone variant H2AX
occur in response to multiple forms of DNA damage (Celeste, 2002). Though the
induction of γH2AX is strongly associated with DNA DSBs sustained from IR treatment,
our lab and others have shown that treatment with TS inhibitors also induce γH2AX
(Ward and Chen, 2001; Yang, 2008; Luo, 2008). TS inhibition has been shown to induce
pRPA, which is a marker for stalled replication forks (Yang, 2008; Yang, 2012). The
question then asked was whether the damage caused by TS inhibition is perceived by the
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cell as a stalled replication fork (pRPA) or as a DSB (γH2AX). Using the TS inhibitor
FdUrd to induce replication stress by deoxynucleotide deprivation, our data shows that
H2AX is dispensable in the response to TS inhibition: H2AX mutation, reduction, or
deficiency does not alter the sensitivity to FdUrd treatment or inhibit the formation of
RAD51 foci. However, in two different cell lines, the kinetics of RPA phosphorylation
was quickened in cells that lack H2AX, indicating that H2AX may play a role in repair
pathway selection in response to deoxynucleotide deprivation.
When a protein is found to be over-expressed in cancer cells and sustains a
critical cellular function, that protein is often examined for potential as drug target. For
example, the human epidermal growth factor HER2 was found to be over-expressed in
multiple forms of breast cancer and conveys a survival advantage by inhibiting apoptosis
(Ménard, 2003). Oncogenic PLK1 is over-expressed in multiple forms of cancer and
canonically functions to regulate mitosis. Several recent publications indicate an
additional role for PLK1 in overcoming replication stress, including the phosphorylation
of key proteins (Trenz, 2008; Song, 2011; Yata, 2012; Ragland, 2013). Thus, PLK1 is an
ideal target for drug development due to its over-expression in cancer and multiple
functions. Using the RNR inhibitor HU to induce replication stress and BI-2536 to inhibit
PLK1, our data shows that this co-treatment reduces PLK1 expression, RPA
phosphorylation is reduced and the formation of RAD51 foci appear to be reduced in size
and number in comparison to HU only treated cells. Decreased RAD51 foci formation is
in agreement with published data (Yata, 2012). The evidence showing RPA as a probable
phospho-substrate of oncogenic PLK1 is a novel finding.
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The research presented here enhances the knowledge of how cancer cells respond
to replication stress induced by deoxynucleotide deprivation and the novel actions of
well-studied proteins in response to this type of stress. TS and RNR inhibitors have been
used in chemotherapy for a number of years but the finding that RPA phosphorylation
kinetics are altered in response to H2AX status shows that there is still more to learn
about the damage response to this class of drug. As well, the finding that pairing a drug
that induces deoxynucleotide deprivation with a PLK1 inhibitor decreases damage
response and repair signals indicate that combination treatments deserve more attention
in both the laboratory and in clinical trials.

4.2 FUTURE DIRECTIONS
Several points have not yet been investigated in this project that would further
clarify the response and repair pathways activated in response to deoxynucleotide
deprivation. In the future, efforts will be focused primarily on oncogenic PLK1:
discovery of phospho-substrates within DNA replication stress, how the inhibition of
PLK1 during replication stress influences cell repair or death decisions and the markers
thereof, and how changes in the expression level of PLK1 potentially alter the response
of cancer cells to DNA damage. This route of research is advantageous due to the number
of PLK1 inhibitors that are currently in clinical trials or in development. Knowledge of
the molecular responses of cancer cells to oncogenic PLK1 inhibition in combination
with replication stress could then be exploited clinically to develop new therapeutic
combinations.

33

REFERENCES
Abraham, R. T. (2001) Cell cycle checkpoint signaling through the ATM and ATR
kinases. Genes and Development 15: 2177-2196.
Adjei, A. A. (2004) Pemetrexed (ALIMTA), a Novel Multitargeted Antineoplastic Agent.
Clinical Cancer Research 10: 4276.
Andrews, C. A. and Clarke, D. J. (2005) MRX (Mre11/Rad50/Xrs2) Mutants Reveal
Dual Intra-S-Phase Checkpoint Systems in Budding Yeast. Cell Cycle 4 (8): 1073-1077.
Barlow, J. H., Faryabi, R. B., Callén, E., Wong, N., Malhowski, A., Chen, H. T.,
Gutierrez-Crus, G., Sun, H-W., McKinnon, P., Wright, G., Casellas, R., Robbiani, D. F.,
Staudt, L., Fernandez-Capetillo, O., and Nussenzweig, A. (2013) Identification of Early
Replicating Fragile Sites that Contribute to Genome Instability. Cell 152: 620-632.
Binz, S. K., Sheehan, A. M., and Wold, M. S. (2004) Replication Protein A
phosphorylation and the cellular response to DNA damage. DNA Repair 3: 1015-1024.
Burgers, P. M. (1998) Eukaryotic DNA polymerases in DNA replication and DNA repair.
Chromosome 107 (4): 18-27.
Burhans, W. C., Vassilev, L. T., Caddle, M. S., Heintz, N. H., and DePamphills, M. L.
(1990) Identification of an origin of bidirectional DNA replication in mammalian
chromosomes. Cell 62 (5): 955-965.
Burhans, W and Weinberger, M. (2007). DNA replication stress, genome instability and
aging. Nucleic Acids Research 35: 7545-7556.
Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M-C., Shaikh, N.,
Domingo, E., Kanu, N., Dewhurst, S. M., Gronroos, E., Chew, S. K., Rowan, A. J.,
Schenk, A., Sheffer, M., Howell, M., Kschischo, M., Behrens, A., Helleday, T., Bartek,
J., Tomlinson, I., and Swanton, C. (2013) Replication stress links structural and
numerical cancer chromosomal instability. Nature 494: 492-499.
Byun, T. S., Pacek, M., Y, M-C., Walter, J. C., and Cimprich, K. A. (2005) Functional
uncoupling of MCM helicase and DNA polymerase activities activates the ATRdependent checkpoint. Genes & Development 19: 1040-1052.

34

Celeste, A., Petersen, S., Romanienko, P. J., Fernandez-Capetillo, O., Chen H. T.,
Sedelnikova, O. A., Reina-San-Martin, B., Coppola, V., Meffre, E., Difilippantonio, M.
J., Redon, C., Pilch, D. R., Olaru, A., Eckhaus, M., Camerini-Otero, R. D., Tessarollo, L.,
Livak, F., Manova, K., Bonner, W. M., Nussenzweig, M. C., and Nussenzweig, A. (2002)
Genomic Instability in Mice Lacking Histone H2AX. Science 296: 922-929.
Chabosseau, P., Buhagiar-Labarchede, G., Onclercq-Delic, R., Lambert, S., Debatisse,
M., Brison, O., and Amor-Gueret, M. (2011) Pyrimidine pool imbalance induced by
BLM helicase deficiency contributes to genetic instability in Bloom syndrome. Nature
Communications 2 (368).
Cleaver, J. E. (2011) γH2Ax: Biomarker of Damage or Functional Participant in DNA
Repair “All that Glitters is not Gold!” Photochemistry and Photobiology 87: 1230-1239.
Flynn, R. L. and Zou, L. (2011) ATR: a master conductor of cellular responses to DNA
replication stress. Trends Biochem Sci 36 (3): 133-140.
Forment, J. V., Blasius, M, Guerini, I., and Jackson, S. P. (2011) Structure-Specific DNA
Endonuclease Mus81/Eme1 Generates DNA Damage Causes by Chk1 Inactivation. PLoS
ONE 6 (8).
Golsteyn, R. M., Schultz, S. J., Bartek, J., Ziemiecki, A., Ried, T., and Nigg, E. A. (1994)
Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue
of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci
107 (6): 1509-1517.
Gray, Jr, P. J., Bearss, D. J., Han, H., Nagle, R., Tsao, M-S., Dean, N., and Von Hoff, D.
D. (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in
pancreatic cancer. Molecular Cancer Therapeutics 3: 641.
Hanahan, D. and Weinberg, R. A. (2000) The Hallmarks of Cancer. Cell 100: 57-70.
James, S. J., Miller, B. J., Basnakian, A. G., Pogribny, I. P., Pogribna, M., and
Muskhelishvili, L. (1997) Apoptosis and proliferation under conditions of
deoxynucleotide pool imbalance in liver of folate/methyl deficient rats. Cacinogenesis 18
(2): 287-293.
Jang, Y-J., Kim, Y. S., and Kim, W. H. (2006) Oncogenic effect of Polo-like kinase 1
expression in human gastric carcinomas. International Journal of Oncology 29 (3): 589594.
Karnani, N. and Dutta, A. (2011) The effect of the intra-S-phase checkpoint on origins of
replication in human cells. Genes and Development 25: 621-633.
Liu, J-S., Kuo, S-R., and Melendy, T. (2006) Phosphorylation of replication protein A by
S-phase checkpoint kinases. DNA Repair 5 (3): 369-380.

35

Luo, Y., Walla, M., and Wyatt, M. D. (2008) Uracil incorporation into genomic DNA
does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.
DNA Repair 7: 162-169.
Ménard, S., Tagliabue, E., Campiqlio, M., and Pupa, S. M. (2000) Role of HER2 gene
overexpression in breast carcinoma. Journal of Cell Physiology 182 (2): 150-162.
Parsels, L. A., Parsels, J. D., Tai, D. C-H., Coughlin, D. J., and Maybaum, J. (2004) 5Fluoro-2’-Deoxyuridine-Induced cdc25A Accumulation Correlates with Premature
Mitotic Entry and Clonogenic Death in Human Colon Cancer Cells. Cancer Research 64:
6588-6594.
Pellegrino, R., Clavisi, D. F., Ladu, S., Ehemann, V., Staniscia, T., Evert, M.,
Dombrowski, F., Schirmacher, P., and Longerich, T. (2010) Oncogenic and tumor
suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51
(3): 857-868.
Ragland, R. L., Patel, S., Rivard, R. S., Smith, K., Peters, A. A., Bielinsky, A-K., and
Brown, E. J. (2013) RNF4 and PLK1 are required for replication fork collapse in ATRdeficient cells. Genes and Development 27: 2259-2273.
Revet, I., Feeney, L., Bruguera, S., Wilson, W., Dong, T. K., Oh, D. H., Dankort, D., and
Cleaver, J. E. (2011) Functional relevance of the histone γH2AX in the response to DNA
damaging agents. PNAS 108 (21): 8663-8667.
Shrivastav, M, De Haro, L. P., and Nickoloff, J. A. (2008) Regulation of DNA doublestrand break repair pathway choice. Cell Research 18 (1): 134-147.
Singh, N., Basnet, H., Wiltshire, T. D., Mohammad, D. H., Thompson, J. R., Heroux, A.,
Botuyan, M. V., Yaffe, M. B., Couch, F. J., Rosenfeld, M. G., and Mer, G. (2012) Dual
recognition of phosphoserine and phosphotyrosine in hisotone variant H2A.X by DNA
damage response protein MCPH1. PNAS 109 (36): 14381-14386.
Sirbu, B. M., Couch, F. B., Feigerle, J. T., Bhaskara, S., Hiebert, S. W., and Cortez, D.
(2011) Analysis of protein dynamics at active, stalled, and collapsed replication forks.
Genes and Development 25: 1320-1327.
Song, S., Wheeler, L. J., and Mathews, C. K. (2003) Doxyribonucleotide Pool Imbalance
Stimulates Deletions in HeLa Cell Mitochondrial DNA. JBC 278: 43893-43896.
Song, B., Liu, X. S., Davis, K., and Liu, X. (2011) Plk1 Phosphorylation of Orc2
Promotes DNA Replication under Conditions of Stress. Molecular and Cellular Biology
31(23): 4844.
Song, B, Liu, X. S, and Liu, X. (2012) Polo-like kinase 1 (Plk1): an Unexpected Player in
DNA Replication. Cell Division 7 (3).

36

Song, B., Liu, X. S., Rice, S. J., Kuang, S., Elzey, B. D., Konieczny, S. F., Ratliff, T. L.,
Hazbun, T., Chiorean, E. G., and Liu, X. (2013) Plk1 Phosphorylation of Orc2 and Hbo1
Contributes to Gemcitabine Resistance in Pancreatic Cancer. Molecular Cancer
Therapeutics 12: 58-68.
Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M.,
Gurtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G. R., Kraut, N.,
Peters, J. M., and Rettig, W. J. (2007) BI 2536, a potent and selective inhibitor of pololike kinase 1, inhibits tumor growth in vivo. Current Biology 17(4): 316-322.
Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K., Kimura, M.,
Okano, Y., and Saji, S. (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary
colorectal cancers. Cancer Science 94 (2): 148-152.
Takemura, H., Rao, V. A., Sorder, O., Furuta, T., Miao, Z-H., Meng, L. H., Zhang, H.,
and Pommier, Y. (2006) Defective Mre11-dependent Activation of Chk2 by Ataxia
Telangiectasia Mutated in Colorectal Carcinoma Cells in Replication-dependent DNA
Double Strand Breaks. The Journal of Biological Chemistry 281 (41): 30814-30823.
Trenz, K., Errico, A., and Constanzo, V. (2008) Plx1 is required for chromosomal DNA
replication under stressful conditions. EMBO Journal 27: 876-885.
Van Cutsem, E. Cunningham, D. Maroun, J., Cervantes, A., and Glimelius, B. (2002)
Raltitrexed: current clinical status and future directions. Annals of Oncology 13 (4): 513522.
van Vugt, M., Smits, V., Klompmaker, R, and Medema, R. (2001) Inhibition of Polo-like
Kinase-1 by DNA Damage Occurs in an ATM- or ATR-dependent Fashion. Journal of
Biological Chemistry 276(45): 41656-41660.
Vazquez-Padua, M., Risueno, C., and Fischer, P. H. (1989) Regulation of the Activation
of Fluorodeoxyuridine by Substrate Competition and Feedback Inhibition in 647V Cells.
Cancer Research 49: 618-624.
Ward, I. M. and Chen, J. (2001) Histone H2AX is phosphorylated in an ATR-dependent
manner in response to replicational stress. Journal of Biological Chemistry 276: 4775947762.
Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K., Loening, S.,
Dietel, M., and Kristiansen, G. (2004) Polo-like kinase 1 is overexpressed in prostate
cancer and linked to higher tumor grades. The Prostate 60 (3): 240-245.
Willis, N. and Rhind, N. (2009) Regulation of DNA replication by the S-phase DNA
damage checkpoint. Cell Division 4 (13).

37

Wold, M. (1997) Replication protein A: a heterotrimeric, single-stranded DNA-binding
protein required for eukaryotic DNA metabolism. Annu Rev Biochem 66: 61-92.
Xie, A., Hartlerode, A., Stucki, M., Odate, S., Puget, N., Kwok, A., Nagaraju, G., Yan,
C., Alt, F. W., Chen, J., Jackson, S. P., and Scully, R. (2007) Distinct Roles of
Chromatin-Associated Proteins MDC1 and 53 BP1 in Mammalian Double-Strand Break
Repair. Molecular Cell 28: 1045-1057.
Yang, Z., Waldman, A. S., and Wyatt, M. D. (2008) DNA damage and homologous
recombination signaling induced by thymidylate deprivation. Biochemical Pharmacology
76: 989-996.
Yang, Z, Waldman, A. S., and Wyatt, M. D. (2012) Expression and regulation of RAD51
mediate cellular responses to chemotherapeutics. Biochemical Pharmacology 83: 741745.
Yarbo, J. W. (1992) Mechanism of action of hydroxyurea. Semin Oncol 19 (3 Suppl 9):
1-10.
Yata, K., Lloyd, J., Maslen, S., Bleuyard, J-Y., Skehel, M., Smerdon, S. J., and Easahi, F.
(2012) Plk1 and CK2 Act in Concert to Regulate RAD51 during DNA Double Strand
Break Repair. Molecular Cell 45: 371-383.
Ye, X., Franco, A. A., Santos, H., Nelson, D. M., Kaufman, P. D., and Adams, P. D.
(2003) Defective S-phase Chromatin Assembly Causes DNA Damage, Activation of the
S-phase Checkpoint, and S-phase Arrest. Molecular Cell 11 (2): 341-351.
Yim, H. (2013) Current clinical trials with polo-like kinase 1 inhibitors in solid tumors.
Anticancer Drugs 24 (10): 999-1006.
Zhang, W-H., Poh, A, Fanous, A. A., and Eastman, A. (2006) DNA damage-induced Sphase arrest in human breast cancer depends on Chk1, but G2 arrest can occur
independently of Chk1, Chk2, or MAPKAPK2. Cell Cycle 7 (11): 1668-1677.
Zhou, B-B. S. and Elledge, S. J. (2000) The DNA damage response: putting checkpoints
in perspective. Nature 408: 433-439.
Zou, J., Rezvani, K., Wang, H., Lee, K. S., and Zhang, D. (2013). BRCA1 downregulates
the kinase activity of Polo-like kinase 1 in response to replication stress. Cell Cycle
12(14): 2255-2265.

38

KD 24 h

KD Un

WT Un

WT 24 h

APPENDIX A – SUPPLEMENTAL DATA

H2AX
β-actin

Figure A.1. H2AX knock-down in HCT116 by shRNA silencing. HCT116 H2AXproficient (WT) and H2AX-reduced (KD) cells were treated for 24 h with 10 μM FdUrd
and probed for H2AX. Comparing untreated (Un) WT and KD lanes, there is a reduction
in total H2AX in the KD sub-line. We also noted that H2AX appears to be induced by
FdUrd treatment. β-actin is shown as a loading control.
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Figure A.2. Cell survival assays using alternative TS inhibitor Pemetrexed (PMX) that
induces deoxynucleotide deprivation. MEF and HCT116 cells were treated for 24 h with
PMX, followed by 3 days in drug-free media. The survival curves for the MEFs indicate
that the response to TS inhibition by PMX may depend on H2AX; however, HCT116
cells are not affected by decreased H2AX expression. PMX has other targets other than
TS, which may account for the differences in toxicity seen in the MEFs. N=3.
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Figure A.3. Cell survival assays using alternative TS inhibitor Raltitrexed (RTX) that
induces deoxynucleotide deprivation. MEF and HCT116 cells were treated for 24 h with
RTX, followed by 3 days in drug-free media. The survival curves for the MEFs indicate
that the response to TS inhibition by RTX may depend on H2AX; however, HCT116
cells are not affected by decreased H2AX expression. RTX has other targets other than
TS, which may account for the differences in toxicity seen in the MEFs. N=3.
EV
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Figure A.4. Overlay of RAD51 and DAPI in MEFs. To show that the RAD51 foci that
formed in response to 24 h of 10 μM FdUrd treatment were located in the nucleus, the
images for RAD51 (Red) and the DAPI-stained DNA (Blue) were overlaid using the
MetaMorph imaging software. As shown above, the RAD51 foci are located within the
nucleus.
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Figure A.5. Immunofluorescent staining of HT29 cells treated with BI-2536. HT29 cells
were treated for 10 h with 30 nM BI-2536. Cells arrested in mitosis (yellow arrow) had
condensed chromosomes, pan-nuclear staining of pRPA, and pan-nuclear staining of
PLK1 with localization around the ends of the chromosomes. DNA: Blue, pRPA: Red,
and PLK1: Green. Images taken at 100x on the Nikon Eclipse E600 microscope.
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